Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Group 1 - Crescent Biopharma, Inc. is focused on developing CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody aimed at treating solid tumors [1] - The company will present at the Jefferies London Healthcare Conference on November 19, 2024 [1][2] - Crescent has entered into an acquisition agreement with GlycoMimetics, Inc., and the combined entity will continue under the name Crescent [2] Group 2 - Crescent Biopharma's pipeline includes three programs that leverage validated biology to expedite the development of potentially best-in-class therapeutics for solid tumors [3]